{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:48:26Z","timestamp":1787028506589,"version":"build-2736575974"},"reference-count":50,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,3,18]],"date-time":"2023-03-18T00:00:00Z","timestamp":1679097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003827","name":"Hungarian National Research, Development, and Innovation Office (NKFIH)","doi-asserted-by":"publisher","award":["FK20_134253"],"award-info":[{"award-number":["FK20_134253"]}],"id":[{"id":"10.13039\/501100003827","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003827","name":"Hungarian National Research, Development, and Innovation Office (NKFIH)","doi-asserted-by":"publisher","award":["K21_137948"],"award-info":[{"award-number":["K21_137948"]}],"id":[{"id":"10.13039\/501100003827","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003827","name":"Hungarian National Research, Development, and Innovation Office (NKFIH)","doi-asserted-by":"publisher","award":["739593"],"award-info":[{"award-number":["739593"]}],"id":[{"id":"10.13039\/501100003827","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003827","name":"Hungarian National Research, Development, and Innovation Office (NKFIH)","doi-asserted-by":"publisher","award":["BO\/00125\/22"],"award-info":[{"award-number":["BO\/00125\/22"]}],"id":[{"id":"10.13039\/501100003827","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003827","name":"Hungarian National Research, Development, and Innovation Office (NKFIH)","doi-asserted-by":"publisher","award":["\u00daNKP-22-5-SE-7"],"award-info":[{"award-number":["\u00daNKP-22-5-SE-7"]}],"id":[{"id":"10.13039\/501100003827","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003827","name":"Hungarian National Research, Development, and Innovation Office (NKFIH)","doi-asserted-by":"publisher","award":["EFOP-3.6.3-VEKOP-16-2017-00009"],"award-info":[{"award-number":["EFOP-3.6.3-VEKOP-16-2017-00009"]}],"id":[{"id":"10.13039\/501100003827","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003827","name":"Hungarian National Research, Development, and Innovation Office (NKFIH)","doi-asserted-by":"publisher","award":["TKP2021-EGA-24"],"award-info":[{"award-number":["TKP2021-EGA-24"]}],"id":[{"id":"10.13039\/501100003827","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003827","name":"Hungarian National Research, Development, and Innovation Office (NKFIH)","doi-asserted-by":"publisher","award":["TKP2021-NVA-15"],"award-info":[{"award-number":["TKP2021-NVA-15"]}],"id":[{"id":"10.13039\/501100003827","id-type":"DOI","asserted-by":"publisher"}]},{"name":"EU\u2019s Horizon 2020 research and innovation program","award":["FK20_134253"],"award-info":[{"award-number":["FK20_134253"]}]},{"name":"EU\u2019s Horizon 2020 research and innovation program","award":["K21_137948"],"award-info":[{"award-number":["K21_137948"]}]},{"name":"EU\u2019s Horizon 2020 research and innovation program","award":["739593"],"award-info":[{"award-number":["739593"]}]},{"name":"EU\u2019s Horizon 2020 research and innovation program","award":["BO\/00125\/22"],"award-info":[{"award-number":["BO\/00125\/22"]}]},{"name":"EU\u2019s Horizon 2020 research and innovation program","award":["\u00daNKP-22-5-SE-7"],"award-info":[{"award-number":["\u00daNKP-22-5-SE-7"]}]},{"name":"EU\u2019s Horizon 2020 research and innovation program","award":["EFOP-3.6.3-VEKOP-16-2017-00009"],"award-info":[{"award-number":["EFOP-3.6.3-VEKOP-16-2017-00009"]}]},{"name":"EU\u2019s Horizon 2020 research and innovation program","award":["TKP2021-EGA-24"],"award-info":[{"award-number":["TKP2021-EGA-24"]}]},{"name":"EU\u2019s Horizon 2020 research and innovation program","award":["TKP2021-NVA-15"],"award-info":[{"award-number":["TKP2021-NVA-15"]}]},{"DOI":"10.13039\/501100003825","name":"Hungarian Academy of Sciences","doi-asserted-by":"publisher","award":["FK20_134253"],"award-info":[{"award-number":["FK20_134253"]}],"id":[{"id":"10.13039\/501100003825","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003825","name":"Hungarian Academy of Sciences","doi-asserted-by":"publisher","award":["K21_137948"],"award-info":[{"award-number":["K21_137948"]}],"id":[{"id":"10.13039\/501100003825","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003825","name":"Hungarian Academy of Sciences","doi-asserted-by":"publisher","award":["739593"],"award-info":[{"award-number":["739593"]}],"id":[{"id":"10.13039\/501100003825","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003825","name":"Hungarian Academy of Sciences","doi-asserted-by":"publisher","award":["BO\/00125\/22"],"award-info":[{"award-number":["BO\/00125\/22"]}],"id":[{"id":"10.13039\/501100003825","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003825","name":"Hungarian Academy of Sciences","doi-asserted-by":"publisher","award":["\u00daNKP-22-5-SE-7"],"award-info":[{"award-number":["\u00daNKP-22-5-SE-7"]}],"id":[{"id":"10.13039\/501100003825","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003825","name":"Hungarian Academy of Sciences","doi-asserted-by":"publisher","award":["EFOP-3.6.3-VEKOP-16-2017-00009"],"award-info":[{"award-number":["EFOP-3.6.3-VEKOP-16-2017-00009"]}],"id":[{"id":"10.13039\/501100003825","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003825","name":"Hungarian Academy of Sciences","doi-asserted-by":"publisher","award":["TKP2021-EGA-24"],"award-info":[{"award-number":["TKP2021-EGA-24"]}],"id":[{"id":"10.13039\/501100003825","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003825","name":"Hungarian Academy of Sciences","doi-asserted-by":"publisher","award":["TKP2021-NVA-15"],"award-info":[{"award-number":["TKP2021-NVA-15"]}],"id":[{"id":"10.13039\/501100003825","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015498","name":"New National Excellence Program of the Ministry for Innovation and Technology","doi-asserted-by":"publisher","award":["FK20_134253"],"award-info":[{"award-number":["FK20_134253"]}],"id":[{"id":"10.13039\/501100015498","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015498","name":"New National Excellence Program of the Ministry for Innovation and Technology","doi-asserted-by":"publisher","award":["K21_137948"],"award-info":[{"award-number":["K21_137948"]}],"id":[{"id":"10.13039\/501100015498","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015498","name":"New National Excellence Program of the Ministry for Innovation and Technology","doi-asserted-by":"publisher","award":["739593"],"award-info":[{"award-number":["739593"]}],"id":[{"id":"10.13039\/501100015498","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015498","name":"New National Excellence Program of the Ministry for Innovation and Technology","doi-asserted-by":"publisher","award":["BO\/00125\/22"],"award-info":[{"award-number":["BO\/00125\/22"]}],"id":[{"id":"10.13039\/501100015498","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015498","name":"New National Excellence Program of the Ministry for Innovation and Technology","doi-asserted-by":"publisher","award":["\u00daNKP-22-5-SE-7"],"award-info":[{"award-number":["\u00daNKP-22-5-SE-7"]}],"id":[{"id":"10.13039\/501100015498","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015498","name":"New National Excellence Program of the Ministry for Innovation and Technology","doi-asserted-by":"publisher","award":["EFOP-3.6.3-VEKOP-16-2017-00009"],"award-info":[{"award-number":["EFOP-3.6.3-VEKOP-16-2017-00009"]}],"id":[{"id":"10.13039\/501100015498","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015498","name":"New National Excellence Program of the Ministry for Innovation and Technology","doi-asserted-by":"publisher","award":["TKP2021-EGA-24"],"award-info":[{"award-number":["TKP2021-EGA-24"]}],"id":[{"id":"10.13039\/501100015498","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015498","name":"New National Excellence Program of the Ministry for Innovation and Technology","doi-asserted-by":"publisher","award":["TKP2021-NVA-15"],"award-info":[{"award-number":["TKP2021-NVA-15"]}],"id":[{"id":"10.13039\/501100015498","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Complementary Research Excellence Program","award":["FK20_134253"],"award-info":[{"award-number":["FK20_134253"]}]},{"name":"Complementary Research Excellence Program","award":["K21_137948"],"award-info":[{"award-number":["K21_137948"]}]},{"name":"Complementary Research Excellence Program","award":["739593"],"award-info":[{"award-number":["739593"]}]},{"name":"Complementary Research Excellence Program","award":["BO\/00125\/22"],"award-info":[{"award-number":["BO\/00125\/22"]}]},{"name":"Complementary Research Excellence Program","award":["\u00daNKP-22-5-SE-7"],"award-info":[{"award-number":["\u00daNKP-22-5-SE-7"]}]},{"name":"Complementary Research Excellence Program","award":["EFOP-3.6.3-VEKOP-16-2017-00009"],"award-info":[{"award-number":["EFOP-3.6.3-VEKOP-16-2017-00009"]}]},{"name":"Complementary Research Excellence Program","award":["TKP2021-EGA-24"],"award-info":[{"award-number":["TKP2021-EGA-24"]}]},{"name":"Complementary Research Excellence Program","award":["TKP2021-NVA-15"],"award-info":[{"award-number":["TKP2021-NVA-15"]}]},{"DOI":"10.13039\/501100002332","name":"Kerpel Talent Award of Semmelweis University","doi-asserted-by":"publisher","award":["FK20_134253"],"award-info":[{"award-number":["FK20_134253"]}],"id":[{"id":"10.13039\/501100002332","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002332","name":"Kerpel Talent Award of Semmelweis University","doi-asserted-by":"publisher","award":["K21_137948"],"award-info":[{"award-number":["K21_137948"]}],"id":[{"id":"10.13039\/501100002332","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002332","name":"Kerpel Talent Award of Semmelweis University","doi-asserted-by":"publisher","award":["739593"],"award-info":[{"award-number":["739593"]}],"id":[{"id":"10.13039\/501100002332","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002332","name":"Kerpel Talent Award of Semmelweis University","doi-asserted-by":"publisher","award":["BO\/00125\/22"],"award-info":[{"award-number":["BO\/00125\/22"]}],"id":[{"id":"10.13039\/501100002332","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002332","name":"Kerpel Talent Award of Semmelweis University","doi-asserted-by":"publisher","award":["\u00daNKP-22-5-SE-7"],"award-info":[{"award-number":["\u00daNKP-22-5-SE-7"]}],"id":[{"id":"10.13039\/501100002332","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002332","name":"Kerpel Talent Award of Semmelweis University","doi-asserted-by":"publisher","award":["EFOP-3.6.3-VEKOP-16-2017-00009"],"award-info":[{"award-number":["EFOP-3.6.3-VEKOP-16-2017-00009"]}],"id":[{"id":"10.13039\/501100002332","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002332","name":"Kerpel Talent Award of Semmelweis University","doi-asserted-by":"publisher","award":["TKP2021-EGA-24"],"award-info":[{"award-number":["TKP2021-EGA-24"]}],"id":[{"id":"10.13039\/501100002332","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002332","name":"Kerpel Talent Award of Semmelweis University","doi-asserted-by":"publisher","award":["TKP2021-NVA-15"],"award-info":[{"award-number":["TKP2021-NVA-15"]}],"id":[{"id":"10.13039\/501100002332","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Research, Development, and Innovation Fund","award":["FK20_134253"],"award-info":[{"award-number":["FK20_134253"]}]},{"name":"National Research, Development, and Innovation Fund","award":["K21_137948"],"award-info":[{"award-number":["K21_137948"]}]},{"name":"National Research, Development, and Innovation Fund","award":["739593"],"award-info":[{"award-number":["739593"]}]},{"name":"National Research, Development, and Innovation Fund","award":["BO\/00125\/22"],"award-info":[{"award-number":["BO\/00125\/22"]}]},{"name":"National Research, Development, and Innovation Fund","award":["\u00daNKP-22-5-SE-7"],"award-info":[{"award-number":["\u00daNKP-22-5-SE-7"]}]},{"name":"National Research, Development, and Innovation Fund","award":["EFOP-3.6.3-VEKOP-16-2017-00009"],"award-info":[{"award-number":["EFOP-3.6.3-VEKOP-16-2017-00009"]}]},{"name":"National Research, Development, and Innovation Fund","award":["TKP2021-EGA-24"],"award-info":[{"award-number":["TKP2021-EGA-24"]}]},{"name":"National Research, Development, and Innovation Fund","award":["TKP2021-NVA-15"],"award-info":[{"award-number":["TKP2021-NVA-15"]}]},{"name":"ELIXIR Hungary","award":["FK20_134253"],"award-info":[{"award-number":["FK20_134253"]}]},{"name":"ELIXIR Hungary","award":["K21_137948"],"award-info":[{"award-number":["K21_137948"]}]},{"name":"ELIXIR Hungary","award":["739593"],"award-info":[{"award-number":["739593"]}]},{"name":"ELIXIR Hungary","award":["BO\/00125\/22"],"award-info":[{"award-number":["BO\/00125\/22"]}]},{"name":"ELIXIR Hungary","award":["\u00daNKP-22-5-SE-7"],"award-info":[{"award-number":["\u00daNKP-22-5-SE-7"]}]},{"name":"ELIXIR Hungary","award":["EFOP-3.6.3-VEKOP-16-2017-00009"],"award-info":[{"award-number":["EFOP-3.6.3-VEKOP-16-2017-00009"]}]},{"name":"ELIXIR Hungary","award":["TKP2021-EGA-24"],"award-info":[{"award-number":["TKP2021-EGA-24"]}]},{"name":"ELIXIR Hungary","award":["TKP2021-NVA-15"],"award-info":[{"award-number":["TKP2021-NVA-15"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The oral, highly selective Bcl2 inhibitor venetoclax has substantially improved the therapeutic landscape of chronic lymphocytic leukemia (CLL). Despite the remarkable response rates in patients with relapsed\/refractory (R\/R) disease, acquired resistance is the leading cause of treatment failure, with somatic BCL2 mutations being the predominant genetic drivers underpinning venetoclax resistance. To assess the correlation between disease progression and the most common BCL2 mutations G101V and D103Y, sensitive (10\u22124) screening for the most common BCL2 mutations G101V and D103Y was performed in 67 R\/R CLL patients during venetoclax single-agent or venetoclax\u2013rituximab combination therapy. With a median follow-up time of 23 months, BCL2 G101V and D103Y were detected in 10.4% (7\/67) and 11.9% (8\/67) of the cases, respectively, with four patients harboring both resistance mutations. Ten out of eleven patients carrying BCL2 G101V and\/or D103Y experienced relapse during the follow-up period, representing 43.5% of the cases (10\/23) showing clinical signs of disease progression. All BCL2 G101V or D103Y variants were detected in patients receiving venetoclax as a continuous single-agent treatment while these mutations were not observed during or after fixed-duration venetoclax therapy. Targeted ultra-deep sequencing of BCL2 uncovered three additional variants in four patient samples obtained at relapse, suggesting convergent evolution and implying a cooperating role of BCL2 mutations in driving venetoclax resistance. This cohort is the largest R\/R CLL patient population reported to date in which BCL2 resistance mutations were investigated. Our study demonstrates the feasibility and clinical value of sensitive screening for BCL2 resistance mutations in R\/R CLL.<\/jats:p>","DOI":"10.3390\/ijms24065802","type":"journal-article","created":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T04:33:31Z","timestamp":1679286811000},"page":"5802","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Landscape of BCL2 Resistance Mutations in a Real-World Cohort of Patients with Relapsed\/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax"],"prefix":"10.3390","volume":"24","author":[{"given":"Lili","family":"Kotmayer","sequence":"first","affiliation":[{"name":"HCEMM-SE Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University, 1085 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3106-9951","authenticated-orcid":false,"given":"Tam\u00e1s","family":"L\u00e1szl\u00f3","sequence":"additional","affiliation":[{"name":"HCEMM-SE Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University, 1085 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2204-7398","authenticated-orcid":false,"given":"G\u00e1bor","family":"Mikala","sequence":"additional","affiliation":[{"name":"South-Pest Central Hospital, National Institute of Hematology and Infectology, 1097 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rich\u00e1rd","family":"Kiss","sequence":"additional","affiliation":[{"name":"HCEMM-SE Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University, 1085 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"L\u00e9vay","sequence":"additional","affiliation":[{"name":"HCEMM-SE Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University, 1085 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lajos L\u00e1szl\u00f3","family":"Hegyi","sequence":"additional","affiliation":[{"name":"HCEMM-SE Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University, 1085 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stef\u00e1nia","family":"Gr\u00f3f","sequence":"additional","affiliation":[{"name":"HCEMM-SE Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University, 1085 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tibor","family":"Nagy","sequence":"additional","affiliation":[{"name":"HCEMM-SE Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University, 1085 Budapest, Hungary"},{"name":"Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8895-3062","authenticated-orcid":false,"given":"G\u00e1bor","family":"Barna","sequence":"additional","affiliation":[{"name":"HCEMM-SE Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University, 1085 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Farkas","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Hematology, Semmelweis University, 1085 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00falia","family":"Weisinger","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Hematology, Semmelweis University, 1085 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsolt","family":"Nagy","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Hematology, Semmelweis University, 1085 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Balogh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Hematology, Semmelweis University, 1085 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"Masszi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Hematology, Semmelweis University, 1085 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"Demeter","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Oncology, Semmelweis University, 1085 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienn","family":"Sul\u00e1k","sequence":"additional","affiliation":[{"name":"2nd Department of Internal Medicine and Cardiology Center, University of Szeged, 6725 Szeged, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n","family":"Kohl","sequence":"additional","affiliation":[{"name":"1st Department of Internal Medicine, Clinical Centre, University of P\u00e9cs, 7622 P\u00e9cs, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussain","family":"Alizadeh","sequence":"additional","affiliation":[{"name":"1st Department of Internal Medicine, Clinical Centre, University of P\u00e9cs, 7622 P\u00e9cs, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikl\u00f3s","family":"Egyed","sequence":"additional","affiliation":[{"name":"Kaposi M\u00f3r University Teaching Hospital of County Somogy, 7400 Kaposv\u00e1r, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piroska","family":"Pettendi","sequence":"additional","affiliation":[{"name":"Het\u00e9nyi G\u00e9za Hospital, Clinic of County J\u00e1sz-Nagykun-Szolnok, 5000 Szolnok, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lajos","family":"Gergely","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rk","family":"Plander","sequence":"additional","affiliation":[{"name":"Markusovszky University Teaching Hospital, 9700 Szombathely, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsolt","family":"Pauker","sequence":"additional","affiliation":[{"name":"Borsod-Aba\u00faj-Zempl\u00e9n County Hospital and University Teaching Hospital, 3515 Miskolc, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e1s","family":"Masszi","sequence":"additional","affiliation":[{"name":"National Institute of Oncology, 1122 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e1s","family":"Matolcsy","sequence":"additional","affiliation":[{"name":"HCEMM-SE Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University, 1085 Budapest, Hungary"},{"name":"Department of Laboratory Medicine, Karolinska Institute, 171 77 Solna, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00f3bert","family":"Sz\u00e1sz","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0729-692X","authenticated-orcid":false,"given":"Csaba","family":"B\u00f6d\u00f6r","sequence":"additional","affiliation":[{"name":"HCEMM-SE Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University, 1085 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2638-5418","authenticated-orcid":false,"given":"Don\u00e1t","family":"Alp\u00e1r","sequence":"additional","affiliation":[{"name":"HCEMM-SE Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University, 1085 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia","volume":"343","author":"Dohner","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1158\/1078-0432.CCR-19-2856","article-title":"Ibrutinib Treatment for First-Line and Relapsed\/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib\/Ii Pcyc-1102 Study","volume":"26","author":"Byrd","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1200\/JCO.2017.76.6840","article-title":"Venetoclax for Patients with Chronic Lymphocytic Leukemia with 17p Deletion: Results from the Full Population of a Phase Ii Pivotal Trial","volume":"36","author":"Stilgenbauer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/blood.2021015014","article-title":"Enduring Undetectable Mrd and Updated Outcomes in Relapsed\/Refractory Cll after Fixed-Duration Venetoclax-Rituximab","volume":"140","author":"Seymour","year":"2022","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting Bcl2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and Obinutuzumab in Patients with Cll and Coexisting Conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_8","first-page":"4315","article-title":"Disease and Patient Characteristics, Patterns of Care, Toxicities, and Outcomes of Chronic Lymphocytic Leukemia (Cll) Patients Treated with Venetoclax: A Multicenter Study of 204 Patients","volume":"130","author":"Mato","year":"2017","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax Plus Obinutuzumab Versus Chlorambucil Plus Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukaemia (Cll14): Follow-up Results from a Multicentre, Open-Label, Randomised, Phase 3 Trial","volume":"21","author":"Zhang","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/10428194.2019.1660974","article-title":"Mechanisms of Intrinsic and Acquired Resistance to Venetoclax in B-Cell Lymphoproliferative Disease","volume":"61","author":"Blombery","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1182\/blood-2017-01-763003","article-title":"Clinicopathological Features and Outcomes of Progression of Cll on the Bcl2 Inhibitor Venetoclax","volume":"129","author":"Anderson","year":"2017","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2022016040","article-title":"Single-Cell Multiomics Reveal the Scale of Multi-Layered Adaptations Enabling Cll Relapse During Venetoclax Therapy","volume":"140","author":"Thijssen","year":"2022","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","article-title":"Acquisition of the Recurrent Gly101val Mutation in Bcl2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia","volume":"9","author":"Blombery","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.3324\/haematol.2019.222588","article-title":"Venetoclax Resistance and Acquired Bcl2 Mutations in Chronic Lymphocytic Leukemia","volume":"104","author":"Tausch","year":"2019","journal-title":"Haematologica"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1182\/blood-2015-10-675009","article-title":"Bcr Signaling Inhibitors Differ in Their Ability to Overcome Mcl-1-Mediated Resistance of Cll B Cells to Abt-199","volume":"127","author":"Bojarczuk","year":"2016","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1182\/blood.2021014304","article-title":"Deregulation and Epigenetic Modification of Bcl2-Family Genes Cause Resistance to Venetoclax in Hematologic Malignancies","volume":"140","author":"Thomalla","year":"2022","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41467-018-03170-7","article-title":"Clonal Dynamics Towards the Development of Venetoclax Resistance in Chronic Lymphocytic Leukemia","volume":"9","author":"Herling","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccell.2019.08.005","article-title":"Mitochondrial Reprogramming Underlies Resistance to Bcl-2 Inhibition in Lymphoid Malignancies","volume":"36","author":"Liu","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1182\/blood-2014-03-560284","article-title":"Acquired Mutations in Bcl2 Family Proteins Conferring Resistance to the Bh3 Mimetic Abt-199 in Lymphoma","volume":"123","author":"Fresquet","year":"2014","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1182\/blood.2019004205","article-title":"Multiple Bcl2 Mutations Cooccurring with Gly101val Emerge in Chronic Lymphocytic Leukemia Progression on Venetoclax","volume":"135","author":"Blombery","year":"2020","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1182\/blood.2019003722","article-title":"Novel Bcl2 Mutations in Venetoclax-Resistant, Ibrutinib-Resistant Cll Patients with Btk\/Plcg2 Mutations","volume":"135","author":"Lucas","year":"2020","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1182\/blood-2019-125457","article-title":"Detection of Multiple Recurrent Novel Bcl2 Mutations Co-Occurring with Bcl2 Gly101val in Patients with Chronic Lymphocytic Leukemia on Long Term Venetoclax","volume":"134","author":"Blombery","year":"2019","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e540","DOI":"10.3324\/haematol.2019.232835","article-title":"Acquisition of the Recurrent Gly101val Mutation in Bcl2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia (Comment to Tausch et al.)","volume":"104","author":"Weiss","year":"2019","journal-title":"Haematologica"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"Iwcll Guidelines for Diagnosis, Indications for Treatment, Response Assessment, and Supportive Management of Cll","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1182\/blood-2017-06-788133","article-title":"Venetoclax for Patients with Chronic Lymphocytic Leukemia Who Progressed During or after Idelalisib Therapy","volume":"131","author":"Coutre","year":"2018","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(17)30909-9","article-title":"Venetoclax for Chronic Lymphocytic Leukaemia Progressing after Ibrutinib: An Interim Analysis of a Multicentre, Open-Label, Phase 2 Trial","volume":"19","author":"Jones","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3324\/haematol.2018.193615","article-title":"Real-World Outcomes and Management Strategies for Venetoclax-Treated Chronic Lymphocytic Leukemia Patients in the United States","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica"},{"key":"ref_28","first-page":"172","article-title":"Identification of Recurrent Genomic Alterations in the Apoptotic Machinery in Cll Patients Treated with Venetoclax Monotherapy","volume":"134","author":"Chyla","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1182\/bloodadvances.2021006211","article-title":"Single-Cell Sequencing Demonstrates Complex Resistance Landscape in Cll and Mcl Treated with Btk and Bcl2 Inhibitors","volume":"6","author":"Thompson","year":"2022","journal-title":"Blood Adv."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"Abt-199, a Potent and Selective Bcl-2 Inhibitor, Achieves Antitumor Activity While Sparing Platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/ajh.26367","article-title":"Chronic Lymphocytic Leukemia: 2022 Update on Diagnostic and Therapeutic Procedures","volume":"96","author":"Hallek","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.20.00948","article-title":"Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations from the Murano Phase Iii Study","volume":"38","author":"Kater","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/bjh.18357","article-title":"Combined Ibrutinib and Venetoclax for Treatment of Patients with Ibrutinib-Resistant or Double-Refractory Chronic Lymphocytic Leukaemia","volume":"199","author":"Hampel","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1182\/bloodadvances.2020001956","article-title":"Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia in the Era of Novel Agents","volume":"4","author":"Roeker","year":"2020","journal-title":"Blood Adv."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2018-05-850461","article-title":"The Phase 3 Duo Trial: Duvelisib Vs Ofatumumab in Relapsed and Refractory Cll\/Sll","volume":"132","author":"Flinn","year":"2018","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1182\/blood.2020008017","article-title":"Tumor-Targeted Nanoparticles Improve the Therapeutic Index of Bcl2 and Mcl1 Dual Inhibition","volume":"137","author":"Tannan","year":"2021","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1182\/blood.2020004782","article-title":"Btk Inhibitor Therapy Is Effective in Patients with Cll Resistant to Venetoclax","volume":"135","author":"Lin","year":"2020","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"5556","DOI":"10.1182\/blood-2018-99-116942","article-title":"Outcomes of Ibrutinib Therapy Given after Prior Venetoclax Therapy in Ibrutinib-Na\u00efve Patients with Relapsed\/Refractory (R\/R) Chronic Lymphocytic Leukemia (Cll)","volume":"132","author":"Brown","year":"2018","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1182\/blood-2018-99-118148","article-title":"Efficacy and Safety of Ibrutinib (Ibr) after Venetoclax (Ven) Treatment in Ibr-Na\u00efve Patients with Relapsed\/Refractory (R\/R) Chronic Lymphocytic Leukemia (Cll): Follow-up of Patients from the Murano Study","volume":"132","author":"Greil","year":"2018","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1182\/bloodadvances.2021005083","article-title":"Outcomes of Patients with Cll Sequentially Resistant to Both Bcl2 and Btk Inhibition","volume":"5","author":"Lew","year":"2021","journal-title":"Blood Adv."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1182\/blood.2022016901","article-title":"Minimal Residual Disease-Driven Treatment Intensification with Sequential Addition of Ibrutinib to Venetoclax in R\/R Cll","volume":"140","author":"Heltai","year":"2022","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e752","DOI":"10.1097\/HS9.0000000000000752","article-title":"Successful Retreatment with Venetoclax in a Patient with Chronic Lymphocytic Leukemia","volume":"6","author":"Jackson","year":"2022","journal-title":"Hemasphere"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1200\/JCO.19.00894","article-title":"Ibrutinib Plus Venetoclax in Relapsed\/Refractory Chronic Lymphocytic Leukemia: The Clarity Study","volume":"37","author":"Hillmen","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood.2020008608","article-title":"Venetoclax and Ibrutinib for Patients with Relapsed\/Refractory Chronic Lymphocytic Leukemia","volume":"137","author":"Niemann","year":"2021","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/bjh.17502","article-title":"Screening and Monitoring of the Btk(C481s) Mutation in a Real-World Cohort of Patients with Relapsed\/Refractory Chronic Lymphocytic Leukaemia During Ibrutinib Therapy","volume":"194","author":"Bodor","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/leu.2015.313","article-title":"A Complementary Role of Multiparameter Flow Cytometry and High-Throughput Sequencing for Minimal Residual Disease Detection in Chronic Lymphocytic Leukemia: An European Research Initiative on Cll Study","volume":"30","author":"Rawstron","year":"2015","journal-title":"Leukemia"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/s41375-017-0007-7","article-title":"Eric Recommendations for Tp53 Mutation Analysis in Chronic Lymphocytic Leukemia-Update on Methodological Approaches and Results Interpretation","volume":"32","author":"Malcikova","year":"2018","journal-title":"Leukemia"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/leu.2017.125","article-title":"Immunoglobulin Gene Sequence Analysis in Chronic Lymphocytic Leukemia: Updated Eric Recommendations","volume":"31","author":"Rosenquist","year":"2017","journal-title":"Leukemia"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/humu.23543","article-title":"Seshat: A Web Service for Accurate Annotation, Validation, and Analysis of Tp53 Variants Generated by Conventional and Next-Generation Sequencing","volume":"39","author":"Tikkanen","year":"2018","journal-title":"Hum. Mutat."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/humu.23035","article-title":"Tp53 Variations in Human Cancers: New Lessons from the Iarc Tp53 Database and Genomics Data","volume":"37","author":"Bouaoun","year":"2016","journal-title":"Hum. Mutat."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/6\/5802\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:58:10Z","timestamp":1760122690000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/6\/5802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,18]]},"references-count":50,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["ijms24065802"],"URL":"https:\/\/doi.org\/10.3390\/ijms24065802","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,18]]}}}